|
|||||||||||||||||||||||||||||||
 |
 |
||||||||||||||||||||||||||||||
 |
Avontec is a Phase 2 biopharmaceutical company addressing large-market indication areas with product candidates derived from its unique and powerful decoy oligonucleotide platform technology. By addressing indication areas characterized by high unmet medical need and by focusing on novel targets, Avontec is positioning itself for maximum value creation based on meeting clinical and regulatory milestones.
The company has pursued low-burn, highly efficient clinical development of its product candidates with the intention of demonstrating clinical proof of concept as early and as convincingly as possible. |
After the initial proof-of-concept has been achieved in the company’s ongoing Phase 2a clinical studies, the company has many options open for partnering of its programs and its technology for additional drug development projects. Avontec has signed an out-licensing agreement with BIOTRONIK for clinical development of AVT-03 for restenosis. |
|||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
